KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Assets (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Assets data on record, last reported at $25.6 billion in Q4 2025.

  • For Q4 2025, Assets rose 13.8% year-over-year to $25.6 billion; the TTM value through Dec 2025 reached $25.6 billion, up 13.8%, while the annual FY2025 figure was $25.6 billion, 13.8% up from the prior year.
  • Assets reached $25.6 billion in Q4 2025 per VRTX's latest filing, up from $24.9 billion in the prior quarter.
  • Across five years, Assets topped out at $25.6 billion in Q4 2025 and bottomed at $12.1 billion in Q1 2021.
  • Average Assets over 5 years is $19.0 billion, with a median of $19.7 billion recorded in 2023.
  • Peak YoY movement for Assets: soared 36.23% in 2021, then dropped 4.34% in 2025.
  • A 5-year view of Assets shows it stood at $13.4 billion in 2021, then soared by 35.13% to $18.2 billion in 2022, then rose by 25.23% to $22.7 billion in 2023, then fell by 0.87% to $22.5 billion in 2024, then increased by 13.8% to $25.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $25.6 billion in Q4 2025, $24.9 billion in Q3 2025, and $24.0 billion in Q2 2025.